Literature DB >> 15279078

Evaluation of two replacement regimens in primary adrenal insufficiency patients. effect on clinical symptoms, health-related quality of life and biochemical parameters.

N Alonso1, M L Granada, A Lucas, I Salinas, J Reverter, A Oriol, A Sanmarti.   

Abstract

OBJECTIVE: To evaluate clinical symptoms, health-related quality of life (HRQL) and biochemical parameters in patients with primary adrenal insufficiency under treatment with two different hydrocortisone regimens (20 mg-0 mg-10 mg/day and 10 mg-5 mg-5 mg/day), each maintained for 3 months and compare results obtained with those in healthy controls. DESIGN, PATIENTS AND METHODS: Twelve patients with primary adrenal insufficiency were studied. Clinical symptoms and HRQL with the Nottingham Health Profile (NHP) were evaluated and Na, K and serum cortisol determined at 09:00 h, 12:30 h and 17:30 h and urinary free cortisol (UFC) throughout the day. Control group comprised 19 healthy subjects.
RESULTS: No differences in specific adrenal insufficiency symptoms were detected between the two regimens. HRQL was worse in energy dimension assessed by the NHP compared to the general population, regardless of 20 mg-0 mg-10 mg/day or 10 mg-5 mg-5 mg/day treatment (p=0.03 and p=0.013). The total NHP score was only adversely affected when patients were on the 10 mg-5 mg-5 mg/day hydrocortisone replacement regimen (p=0.008). Serum cortisol concentrations were higher than controls at 09:00 h, and lower at 17:30 h with both regimens, whereas serum cortisol at 12:30 h and UFC were within the 5th-95th percentile normal range only with the 10 mg-5 mg-5 mg/day regimen.
CONCLUSIONS: Patients with primary adrenal insufficiency had worse HRQL in the NHP energy dimension compared with the general population, regardless of the hydrocortisone regimen although total score for HRQL was worse only with the 10 mg-5 mg-5 mg/day regimen. Patients on the thrice-daily hydrocortisone regimen showed a more physiological cortisol profile, leading us to recommend initially treating patients with this dose and increasing it in the case of impaired HRQL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15279078     DOI: 10.1007/BF03345290

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  27 in total

1.  Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids.

Authors:  E Garbe; J LeLorier; J F Boivin; S Suissa
Journal:  Lancet       Date:  1997-10-04       Impact factor: 79.321

2.  The assessment of glucocorticoid replacement therapy.

Authors:  J P Monson
Journal:  Clin Endocrinol (Oxf)       Date:  1997-03       Impact factor: 3.478

3.  Dehydroepiandrosterone replacement in women with adrenal insufficiency.

Authors:  W Arlt; F Callies; J C van Vlijmen; I Koehler; M Reincke; M Bidlingmaier; D Huebler; M Oettel; M Ernst; H M Schulte; B Allolio
Journal:  N Engl J Med       Date:  1999-09-30       Impact factor: 91.245

4.  Reference standards for cortisol production and 17-hydroxy-corticosteroid excretion during growth: variation in the pattern of excretion of radiolabeled cortisol metabolites.

Authors:  F M Kenny; F H Taylor; C Richards
Journal:  Metabolism       Date:  1970-04       Impact factor: 8.694

5.  Subjective health status in Norwegian patients with Addison's disease.

Authors:  Kristian Løvås; Jon Håvard Loge; Eystein S Husebye
Journal:  Clin Endocrinol (Oxf)       Date:  2002-05       Impact factor: 3.478

6.  The Spanish version of the Nottingham Health Profile: a review of adaptation and instrument characteristics.

Authors:  J Alonso; L Prieto; J M Antó
Journal:  Qual Life Res       Date:  1994-12       Impact factor: 4.147

7.  Steroid replacement in Addison's disease and in subjects adrenalectomized for Cushing's disease: comparison of various glucocorticoids.

Authors:  B A Khalid; C W Burke; D M Hurley; J W Funder; J R Stockigt
Journal:  J Clin Endocrinol Metab       Date:  1982-09       Impact factor: 5.958

8.  Urinary free cortisol in the assessment of hydrocortisone replacement therapy.

Authors:  P J Trainer; K C McHardy; R D Harvey; I W Reid
Journal:  Horm Metab Res       Date:  1993-02       Impact factor: 2.936

9.  Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry.

Authors:  N V Esteban; T Loughlin; A L Yergey; J K Zawadzki; J D Booth; J C Winterer; D L Loriaux
Journal:  J Clin Endocrinol Metab       Date:  1991-01       Impact factor: 5.958

10.  Effect of glucocorticoid replacement therapy on glucose tolerance and intermediary metabolites in hypopituitary adults.

Authors:  K A al-Shoumer; S A Beshyah; R Niththyananthan; D G Johnston
Journal:  Clin Endocrinol (Oxf)       Date:  1995-01       Impact factor: 3.478

View more
  2 in total

Review 1.  Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline.

Authors:  Stefan R Bornstein; Bruno Allolio; Wiebke Arlt; Andreas Barthel; Andrew Don-Wauchope; Gary D Hammer; Eystein S Husebye; Deborah P Merke; M Hassan Murad; Constantine A Stratakis; David J Torpy
Journal:  J Clin Endocrinol Metab       Date:  2016-01-13       Impact factor: 5.958

2.  Recurrent nocturnal hypoglycaemia as a cause of morning fatigue in treated Addison's disease--favourable response to dietary management: a case report.

Authors:  Kristina S Petersen; R Louise Rushworth; Peter M Clifton; David J Torpy
Journal:  BMC Endocr Disord       Date:  2015-10-24       Impact factor: 2.763

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.